⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20743132 | 0.88 | MEN1 (0.39) | — | |
| SCHEMBL15840478 | 0.81 | EPHX2 (0.45) | — | |
| SCHEMBL20744289 | 0.80 | — | — | |
| SCHEMBL20744374 | 0.80 | — | — | |
| SCHEMBL30305342 | 0.80 | — | — | |
| SCHEMBL20744498 | 0.79 | — | — | |
| SCHEMBL20744268 | 0.75 | — | — | |
| SCHEMBL20744291 | 0.75 | — | — | |
| SCHEMBL30305369 | 0.75 | — | — | |
| SCHEMBL20753907 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307385-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-19 | — | — | US | claimed |
| EP-3668853-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | claimed |
| US-20200253967-A1 | NOVEL COMPOUNDS | BioVersys AG (CH) | 2020-08-13 | — | — | US | claimed |
| EP-3668853-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-06-24 | — | — | EP | claimed |
| CN-111225910-A | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-06-02 | — | — | CN | claimed |
| WO-2019034701-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | claimed |
| US-20240307385-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-19 | — | — | US | disclosed |
| US-11969423-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| EP-3668853-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| EP-3668853-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-20200253967-A1 | NOVEL COMPOUNDS | BioVersys AG (CH) | 2020-08-13 | — | — | US | disclosed |
| US-20200253967-A1 | NOVEL COMPOUNDS | BioVersys AG (CH) | 2020-08-13 | — | — | US | disclosed |
| EP-3668853-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| CN-111225910-A | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-06-02 | — | — | CN | disclosed |
| WO-2019034701-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034701-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |